<p>/PRNewswire/ -- Azenta, Inc.（納斯達克代碼：AZTA）今天宣佈，其子公司 Azenta Germany GmbH 已與 THELEMA S.À R.L.簽署了一項具有約束力的協議，以 6300 萬美元的價格出售 Azenta 的 B Medical Systems 業務。該交易預計將在 2026 年 3 月 31 日或之前完成。</p>
<p>“出售 B Medical Systems 的協議標誌着簡化產品組合、優先考慮我們具有最高戰略影響力的核心能力的重要一步，” 首席執行官 John Marotta 表示。“此次出售的收益將用於增強公司實力，併為我們的股東創造長期的盈利價值。”</p>
<p>B Medical Systems 是一家總部位於盧森堡的全球醫療製冷設備製造和分銷商。</p>
<p>William Blair 擔任此次交易的獨家財務顧問，Taylor Wessing 擔任 Azenta 的法律顧問。</p>
<p><strong>關於 Azenta 生命科學</strong></p>
<p>Azenta, Inc.（納斯達克代碼：AZTA）是全球領先的生命科學解決方案提供商，幫助全球生命科學組織更快地將具有影響力的突破和療法推向市場。Azenta 提供全面可靠的冷鏈樣本管理解決方案和多組學服務，涵蓋藥物開發、臨牀研究和先進細胞療法等領域，服務於全球頂尖的製藥、生物技術、學術和醫療機構。我們的全球團隊通過行業領先的品牌（包括 GENEWIZ、FluidX、Ziath、4titude、Limfinity、Freezer Pro 和 Barkey）提供和支持這些產品和服務。</p>
<p>Azenta 總部位於馬薩諸塞州伯靈頓，在北美、歐洲和亞洲開展業務。欲瞭解更多信息，請訪問 www.azenta.com。</p>
<p><strong>關於前瞻性聲明的警示説明</strong></p>
<p>本新聞稿包含前瞻性聲明，包括交易的預計完成日期。這些聲明涉及風險和不確定性，可能導致實際結果與這些聲明所表達或暗示的結果有實質性差異。儘管公司的前瞻性聲明反映了管理層的善意判斷，但這些聲明僅基於公司當前已知的事實和因素。因此，您被警告不要依賴這些前瞻性聲明。本新聞稿中以 8-K 表格發佈的任何前瞻性聲明僅在其發佈之日有效。除非法律要求，否則公司不承擔公開更新或修訂任何前瞻性聲明的義務，無論是由於新信息、未來發展還是其他原因。</p>
<p>投資者聯繫方式：</p>
<p>Yvonne Perron</p>
<p>財務規劃與分析副總裁及投資者關係負責人</p>
<p>ir@azenta.com</p>
<p>Maria Isabel Cuartas</p>
<p>投資者關係經理</p>
<p>ir@azenta.com</p>
<p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/1636185/Azenta_Logo_v3.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/1636185/Azenta_Logo_v3.jpg"/></p>
<p>來源：Azenta</p>

AZTA

<p>Azenta, Inc. 已簽署一項最終協議，將其 B Medical Systems 業務以 6300 萬美元的價格出售給 THELEMA S.À R.L.，預計交易將在 2026 年 3 月 31 日之前完成。首席執行官 John Marotta 表示，此次出售將有助於簡化公司的產品組合，並專注於核心能力。出售所得將用於增強公司的實力並提升股東價值。William Blair 擔任此次交易的財務顧問</p>

<p>, /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that its affiliate, Azenta Germany GmbH, has signed a binding agreement for the sale of Azenta's B Medical Systems business to THELEMA S.À R.L., for a purchase price of US$63 million. The transaction is expected to close on or before March 31, 2026.</p>
<div class="lb-trans"><p>/PRNewswire/ -- Azenta, Inc.（納斯達克代碼：AZTA）今天宣佈，其子公司 Azenta Germany GmbH 已與 THELEMA S.À R.L.簽署了一項具有約束力的協議，以 6300 萬美元的價格出售 Azenta 的 B Medical Systems 業務。該交易預計將在 2026 年 3 月 31 日或之前完成。</p>
</div><p>&#34;The agreement to sell B Medical Systems marks a major step forward in simplifying the portfolio to prioritize our core capabilities with the highest strategic impact,&#34; said John Marotta, President and CEO. &#34;The proceeds from this sale will be deployed to strengthen the company and drive long-term profitable value creation for our shareholders.&#34;</p>
<div class="lb-trans"><p>“出售 B Medical Systems 的協議標誌着簡化產品組合、優先考慮我們具有最高戰略影響力的核心能力的重要一步，” 首席執行官 John Marotta 表示。“此次出售的收益將用於增強公司實力，併為我們的股東創造長期的盈利價值。”</p>
</div><p>B Medical Systems is a global manufacturer and distributor of medical refrigeration devices based in Luxembourg.</p>
<div class="lb-trans"><p>B Medical Systems 是一家總部位於盧森堡的全球醫療製冷設備製造和分銷商。</p>
</div><p>William Blair served as exclusive financial advisor and Taylor Wessing served as legal counsel to Azenta for this transaction.</p>
<div class="lb-trans"><p>William Blair 擔任此次交易的獨家財務顧問，Taylor Wessing 擔任 Azenta 的法律顧問。</p>
</div><p><strong>About Azenta Life Sciences</strong></p>
<div class="lb-trans"><p><strong>關於 Azenta 生命科學</strong></p>
</div><p>Azenta, Inc. (Nasdaq: AZTA) is a leading provider of life sciences solutions worldwide, enabling life science organizations around the world to bring impactful breakthroughs and therapies to market faster. Azenta provides a full suite of reliable cold-chain sample management solutions and multiomics services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. Our global team delivers and supports these products and services through our industry-leading brands, including GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, and Barkey.</p>
<div class="lb-trans"><p>Azenta, Inc.（納斯達克代碼：AZTA）是全球領先的生命科學解決方案提供商，幫助全球生命科學組織更快地將具有影響力的突破和療法推向市場。Azenta 提供全面可靠的冷鏈樣本管理解決方案和多組學服務，涵蓋藥物開發、臨牀研究和先進細胞療法等領域，服務於全球頂尖的製藥、生物技術、學術和醫療機構。我們的全球團隊通過行業領先的品牌（包括 GENEWIZ、FluidX、Ziath、4titude、Limfinity、Freezer Pro 和 Barkey）提供和支持這些產品和服務。</p>
</div><p>Azenta is headquartered in Burlington, MA, with operations in North America, Europe and Asia. For more information, please visit www.azenta.com.</p>
<div class="lb-trans"><p>Azenta 總部位於馬薩諸塞州伯靈頓，在北美、歐洲和亞洲開展業務。欲瞭解更多信息，請訪問 www.azenta.com。</p>
</div><p><strong>Cautionary Note Regarding Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>關於前瞻性聲明的警示説明</strong></p>
</div><p>This press release contains forward-looking statements, including the expected closing date for the transaction. Such statements involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Although the Company's forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by the Company. As a result, you are cautioned not to rely on these forward-looking statements. Any forward-looking statement made in this press release on Form 8-K speaks only as of the date on which it is made. Except as required by applicable law, the Company undertakes no obligation to publicly update or revise any forward-looking statement, whether because of new information, future developments or otherwise.</p>
<div class="lb-trans"><p>本新聞稿包含前瞻性聲明，包括交易的預計完成日期。這些聲明涉及風險和不確定性，可能導致實際結果與這些聲明所表達或暗示的結果有實質性差異。儘管公司的前瞻性聲明反映了管理層的善意判斷，但這些聲明僅基於公司當前已知的事實和因素。因此，您被警告不要依賴這些前瞻性聲明。本新聞稿中以 8-K 表格發佈的任何前瞻性聲明僅在其發佈之日有效。除非法律要求，否則公司不承擔公開更新或修訂任何前瞻性聲明的義務，無論是由於新信息、未來發展還是其他原因。</p>
</div><p>INVESTOR CONTACTS:</p>
<div class="lb-trans"><p>投資者聯繫方式：</p>
</div><p>Yvonne Perron</p>
<div class="lb-trans"><p>Yvonne Perron</p>
</div><p>Vice President, Financial Planning &amp; Analysis, and Investor Relations</p>
<div class="lb-trans"><p>財務規劃與分析副總裁及投資者關係負責人</p>
</div><p>ir@azenta.com</p>
<div class="lb-trans"><p>ir@azenta.com</p>
</div><p>Maria Isabel Cuartas</p>
<div class="lb-trans"><p>Maria Isabel Cuartas</p>
</div><p>Manager, Investor Relations</p>
<div class="lb-trans"><p>投資者關係經理</p>
</div><p>ir@azenta.com</p>
<div class="lb-trans"><p>ir@azenta.com</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/1636185/Azenta_Logo_v3.jpg" alt="" original-src="https://mma.prnewswire.com/media/1636185/Azenta_Logo_v3.jpg"/></p>
<p>SOURCE Azenta</p>
<div class="lb-trans"><p>來源：Azenta</p>
</div>

Azenta 與 THELEMA S.À R.L.簽署最終協議，出售其 B 醫療系統業務 | AZTA 股票新聞